DJIA 18,203.37 -85.26 -0.47%
NASDAQ 4,979.90 -28.20 -0.56%
S&P 500 2,107.78 -9.61 -0.45%
market minute promo

Celgene (NASDAQ: CELG)

118.47 -1.84 (-1.53%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CELG $118.47 -1.53%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $120.00
Previous Close $120.31
Daily Range $116.34 - $120.19
52-Week Range $66.85 - $125.45
Market Cap $94.8B
P/E Ratio 50.34
Dividend (Yield) $0.00 (0.0%)
Volume 6,357,612
Average Daily Volume 5,189,374
Current FY EPS $4.32

Sector

Healthcare

Industry

Drug Makers

Celgene (CELG) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Website: http://www.celgene.com/

News & Commentary

3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year

These three companies could post better growth than Gilead Sciences that allow them to be top performers this year.

Celgene's Abraxane Combination Therapy Cleared in the EU - Analyst Blog

Pioneer Fundamental Growth Fund: Why Is It Revving Up?

Amgen: The Best Biotech Stock You Don't Own

Stocks Extend Losses as Israel Warns U.S. of Nuclear Deal With Iran

Ligand Pharmaceuticals Weakens The Bear Case

3 Stocks Reiterated As A Buy: CELG, CBS, ABT

Innovation, not easy money, is behind the Nasdaq’s return to 5,000

Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF

ABRAXANE Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lu

ABRAXANE Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

Amgen's Long Case Strengthens After Kyprolis Data

See More CELG News...

CELG's Top Competitors

CELG $118.47 (-1.53%)
Current stock: CELG
AMGN $158.56 (-0.67%)
Current stock: AMGN
GILD $102.79 (-1.00%)
Current stock: GILD
$0.00 (0.00%)
Current stock: